Frontlight ResearchEarly access
CompletedNo phase
Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS
Key facts
- Who runs it
- Fondazione Italiana Linfomi - ETS
- Where
- Italy and Spain15 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 300 people enrolled
- Started
- 28 Aug 2018
- Ended
- 2 Oct 2025
- Type of study
- Observational
- Treatments tested
- MRD and clonal evolution
- Record updated
- 27 August 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Diagnosis of IgM monoclonal gammopathy of undetermined significance (Ig-MGUS) or Waldenström's Macroglobulinemia (WM) according to criteria established at the second International Workshop on Waldenström's Macroglobulinemia [1]
- Age ≥ 18 years
- Previously untreated patients (only for the prospective cohort)
- Symptomatic or asymptomatic disease
- Subject understands and voluntarily signs an informed consent form approved by an Independent Ethics Committee (IEC)/Institutional Review Board (IRB)
Who cannot take part
- Active HBV, HCV or HIV infection (antiHBc+ patients with undetectable HBV-DNA are eligible to the study)
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
Multicenter retrospective and prospective observational study including patients with WM or IgM-MGUS evaluated at the time of diagnosis and during the disease course using highly sensitive techniques.
The group in the trial
- Patient enrolled
Part of the patients will be retrospectively enrolled (learning sample) and part prospectively (validation sample)
Treatment: MRD and clonal evolution
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Non-invasive Diagnostics and Monitoring of Minimal Residual Disease and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM Monoclonal Gammopathy of Undetermined Significance
- Record updated
- 27 August 2026